Martin Maron to Pyrazoles
This is a "connection" page, showing publications Martin Maron has written about Pyrazoles.
Connection Strength
1.252
-
Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J. 2025 10 22; 46(40):4076-4086.
Score: 0.859
-
Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11; 393(10):949-960.
Score: 0.219
-
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. JAMA Cardiol. 2026 Aug 01; 11(8):736-746.
Score: 0.058
-
Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. 2026 Jun 23; 47(24):3120-3131.
Score: 0.058
-
Veselka J, Gimeno R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Masri A, Miao ZM, Nassif ME, Olivotto I, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Maron MS. Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients. Am J Cardiol. 2026 Jul 01; 270:133-141.
Score: 0.057